Filing Flows › Biogen (BIIB) › Q2 2026 › vs Q1 2026
Biogen (BIIB) Q2 2026 vs Q1 2026 (quarter over quarter)
Biogen's revenue rose $258M (+10%) from $2.5B in Q1 2026 to $2.7B in Q2 2026. Operating margin 4.8% against 15.2% (-10.4 pts).
Biogen, Q2 2026: revenue $2.7B (+3% year over year), operating margin 4.8%, net earnings $97.5M, operating cash flow $449M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 4.8% | 15.2% | -10.4 pts |
| Net margin | 3.6% | 12.9% | -9.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $258M | +10% |
| Operating profit | $132M | $378M | −$245M | -65% |
| Costs & expenses | $2.6B | $2.1B | $504M | +24% |
| Pre-tax earnings | $132M | $378M | −$245M | -65% |
| Cost of revenue | $777M | $661M | $116M | +18% |
| Research & development | $530M | $539M | −$9.4M | -2% |
| SG&A | $710M | $607M | $102M | +17% |
| Other operating costs | $587M | $293M | $295M | +101% |
| Net earnings | $97.5M | $320M | −$222M | -69% |
| Income tax | $34.9M | $58.2M | −$23.3M | -40% |
| Depreciation & amortization | $236M | $204M | $31.7M | +16% |
| Share-based compensation | $77.4M | $84.0M | −$6.6M | -8% |
| Working capital & other | $37.9M | $37.6M | $300K | +0.8% |
| Operating cash flow | $449M | $646M | −$197M | -30% |
Questions
How much did Biogen's revenue grow quarter over quarter in Q2 2026?
Biogen's revenue rose $258M (+10%) from $2.5B in Q1 2026 to $2.7B in Q2 2026. Operating margin 4.8% against 15.2% (-10.4 pts).